Journal of Zoology and Allied Sciences
Online peer reviewed Journal I Published by COGNIX PRESS
Content available at www.cognixpress.in Online ISSN: XXXX-XXXX

REVIEW ARTICLE
OPEN ACCESS

RATIONAL USE OF ANTIBIOTICS IN INTENSIVE CARE UNIT

NAGA SUBRAHMANYAM S*[1], VADALI SHIVA NAGA LAKSHMI[1], S INDU HARINI[2]

[1]*Vishwa Bharathi College of Pharmaceutical Sciences, N.R.T Road, Perecherla, Medikonduru MD, Guntur-522006, Andhra Pradesh, India*
[2]*Departmnet of Pharmacy Practice, Koringa College of Pharmacy, Korandi, Kaninada, Andhra Pradesh, India*

Corresponding Author
Dr. Naga Subrahmanyam S

Article History: 19.03.2026 Received: 02.04.2026 Revised: Accepted: 16.04.2026

ABSTRACT
Intensive Care Units (ICUs) care for critically ill patients who are highly vulnerable to severe infections, making timely antibiotic therapy essential. In many cases, empirical antibiotics arinitiated before laboratory confirmation to prevent disease progression. However, inappropriate antibiotic prescribing can contribute to antimicrobial resistance, adverse drug reactions, prolonged hospital stays, increased healthcare costs, and poorer patient outcomes. Therefore, rational antibiotic use, guided by clinical assessment, microbiological data, and antimicrobial stewardship principles, is essential to ensure effective treatment, enhance patient safety, and reduce the emergence of antibiotic resistance.

Keywords: *Rational antibiotic use, Intensive Care Unit (ICU), Antimicrobial stewardship, Antimicrobial resistance, Empirical antibiotic therapy.*

INTRODUCTION

OptimizingAntibioticUse in Intensive Care Units

Intensive Care Units (ICUs) treat critically ill patients suffering from severe conditions like sepsis, trauma, and organ failure. Because these patients undergo invasive procedures and have weakened immune systems, they are highly susceptible to hospital-acquired infections, making antibiotics some of the most frequently prescribed drugs in this setting [1].

While delayed treatment can drastically increase mortality rates-requiring immediate, broad-spectrum "empirical" therapy-overusing these powerful drugs has accelerated [2]. Global antimicrobial resistance (AMR). Issues such as incorrect dosing, prolonged prescriptions, and a failure to narrow down treatment after lab results come back further worsen the spread of resistant superbugs [3].

Rational Prescribing & Stewardship:

To combat AMR and safeguard patient health, ICUs must practice rational antibiotic use. This means delivering the precise drug, at the correct dose and duration, tailored to the patient's clinical status and lab results [4].

Antimicrobial Stewardship Programs (ASPs): These programs enforce evidence-based guidelines to optimize drug selection, reduce unnecessary exposure, and minimize adverse side effects [5].

Targeted Diagnostics: Utilizing culture and susceptibility testing to transition from broad-spectrum to targeted therapies (de-escalation).

Clinical Monitoring: Employing therapeutic drug monitoring and precise dose adjustments to fit the complex metabolism of critically ill patients [6].

All collected data were evaluated using descriptive and inferential statistics reported in frequencies, percentages, and means A< 0.05 was established as the threshold for statistical significance [7].

METHODOLOGY: This study was conducted as a narrative literature review to evaluate the rational use of antibiotics in Intensive Care Units (ICUs). A comprehensive literature search was performed using electronic databases, including PubMed, Scopus, Google Scholar, ScienceDirect, Embase, and the Cochrane Library, for articles published between 2015 and 2025 [8]. Keywords such as rational antibiotic use, intensive care unit, antimicrobial stewardship, antimicrobial

resistance, empirical antibiotic therapy, culture-guided therapy, therapeutic drug monitoring, and antibiotic de-escalation were used to identify relevant studies [9].

Original research articles,systematicreviews, meta-analyses, observational studies, and clinical practice guidelines related to antibiotic use in ICU patients were included, while duplicate, non-English, and irrelevant articles were excluded [9]. The selected studies were critically evaluated for their scientific quality and clinical relevance. Data on antibiotic prescribing practices, antimicrobial stewardship strategies, antimicrobial resistance, and clinical outcomes were extracted, compared, and synthesized to provide an evidence-based overview of rational antibiotic use in critically ill patients [11].

CHALLENGES IN ANTIBIOTIC USE IN (Intensive care unit)

1. The Diagnostic Delay

Standard laboratory cultures take between 24 and 72 hours to yield results. This lag forces doctors to guess and use broad-spectrum drugs early on, which can lead to inappropriate or unnecessary medication exposure [12].

2. The Rise of Superbugs

Constant exposure to heavy-duty antibiotics in critical care units has accelerated the mutation of bacteria into multidrug-resistant (MDR) and carbapenem-resistant strains. These superbugs often cause treatment failure and spike mortality rates [13].

3.Unpredictable Body Chemistry (Altered PK/PD)

Severe illness alters how a patient's body processes medicine. Factors like massive fluid shifts, low blood protein, organ failure, or dialysis mean that antibiotics are absorbed, distributed, and cleared in erratic ways, making standard dosing highly unreliable [14].

4 .Drug Interactions

Because ICU patients take numerous medications simultaneously, the risk of negative drug interactions is high. Antibiotics frequently trigger severe complications, including kidney damage, liver toxicity, or dangerous gut infections like Clostridioides difficile [15].

RATIONAL USE PRINCIPLES:

Core Pillars of ICU Antibiotic Stewardship

1. Verification of Infection (Accurate Diagnosis)

Antibioticsmust be reserved strictly for cases with clear clinical indications or confirmed bacterial presence [16]. Clinicians should rely on a combination of physical evaluations, blood work, imaging, and lab cultures to confirm an infection before prescribing, preventing unnecessary drug exposure [17].

2. Immediate, Informed First-Line Treatment (Empirical Therapy)

For patients in critical danger from suspected sepsis or septic shock, broad-spectrum antibiotics must be delivered without delay [18]. Because lab results take time, this initial choice should be a calculated decision based on where the infection likely started, the hospital's local resistance trends, the patient's recent antibiotic history, and their personal risk factors [19].

3. Lab-Based Identification (Microbiological Confirmation)

Whenever safely possible, bodily fluids (such as blood, urine, or sputum) must be sampled before the first dose of antibiotics is given [20]. These lab cultures are vital because they pinpoint the exact pathogen responsible, allowing the medical team to transition from guesswork to precision treatment [21].

4. Narrowing the Scope (De-escalation)

As soon as the lab identifies the specific bacteria and the drugs it responds to, clinicians should swap out broad-spectrum antibiotics for a targeted, narrow-spectrum alternative. This process of de-escalation lowers drug toxicity, limits unnecessary chemical exposure, and actively combats the rise of resist [22].

IMPORTANCE OF RATIONAL ANTIBIOTICS USE IN ICU

The Vital Impact of Rational Antibiotic Use in the ICU

1. Enhancing Patient Survival and Safety

Critically ill patients are highly susceptible to severe infections and sepsis, making targeted antibiotic therapy a matter of life or death [23]. Administering the correct drug at the proper dosage and duration maximizes survival rates and halts organ failure. Furthermore, modifying these doses based on the patient's liver and kidney function significantly reduces dangerous side effects, such as organ toxicity, allergic reactions, and severe gut infections like Clostridioides difficile [24].

2. Combating Antimicrobial Resistance (AMR)

Misusing broad-spectrum antibiotics for extended periods creates an environment where multidrug-resistant organisms (MDROs) thrive. Implementing rational prescribing practices relieves this evolutionary pressure on bacteria [25].) By consistently reviewing patient data and transitioning from broad-spectrum to narrow-spectrum drugs (de-escalation) as soon as lab results allow, clinicians can successfully treat infections without fuel-injecting the global crisis of superbugs [26].

3. Lowering Healthcare Expenditures

When medical teams choose the correct antibiotic from the start and limit the treatment timeline to what is clinically necessary, hospital stays are shortened. This efficient care model reduces the need for incredibly expensive, last-resort medications and cuts down the massive financial deficits associated with managing complex, drug-resistant infections [27].

4. The Power of Institutional Stewardship: Antimicrobial stewardship programs serve as the operational backbone for these praLightner, lab cultures, educating staff, and tracking local resistance trends, these initiatives drastically upgrade the standard of critical care while ensuring that our current life-saving antimicrobials remain effective for the future [28].

SPECIAL POPULATION AND SPECIFIC PATHOGENS

Antibiotic Management in Vulnerable ICU Populations

Critical care requires highly personalized medicine because standard antibiotic dosing often fails in specific patient groups due to drastic changes in how their bodies process medication [29].

1. **Geriatric Patients**

Older adults typically exhibit diminished kidney and liver clearance, suffer from multiple chronic conditions, and take numerous medications simultaneously (polypharmacy). To prevent severe drug toxicities while keeping the treatment effective, antibiotic doses must be carefully calculated based on their actual organ performance [30].

2. Individuals with Kidney Impairment

Because the kidneys are the primary route of elimination for major antibiotic classes-such as \beta\text{-lactams}, aminoglycosides, and vancomycin-impaired renal function can cause dangerous drug accumulation. Relying on creatinine clearance calculations to adjust doses is mandatory to prevent compounding kidney damage (nephrotoxicity) [31].

3**. Individuals with Liver Dysfunction**

Hepatic disease slows down the metabolism of specific antimicrobials, including metronidazole, clindamycin, and macrolides. Clinicians must closely monitor liver enzymes and adjust dosages to prevent toxic drug buildup [32].

4. Obese Critically Ill Patients

Severe obesity radically changes how a drug distributes throughout body fat and fluids, as well as how quickly it clears. Using specialized weight-based dosing equations and tracking actual blood levels through therapeutic drug monitoring ensures these patients receive enough medication to clear the infection [33].

5. **Patients on Life Support (RRT or ECMO)**

Advanced life-support therapies like Continuous Renal Replacement Therapy (CRRT/dialysis) and Extracorporeal Membrane Oxygenation (ECMO/heart-lung bypass) strip medications from the blood or alter fluid dynamics unpredictably. Managing these patients requires custom, real-time dosing strategies driven by blood-level monitoring [34].

SPECIFIC PATHOGENS

1. **Methicillin-Resistant Staphylococcus aureus (MRSA)**

MRSA is a common cause of ventilator-associated pneumonia, bloodstream infections, and skin and soft tissue infections in ICU patients. Appropriate agents include vancomycin or linezolid based on susceptibility results and clinical condition [35].

2. Pseudomonas aeruginosa

This pathogen commonly causes ventilator-associated pneumonia and bloodstream infections. Empirical therapy should consider local resistance patterns and may include antipseudomonal β-lactams, carbapenems, or combination therapy in high-risk patients [36].

3. Acinetobacter baumannii

This organism frequently exhibits multidrug resistance and is associated with healthcare-associated pneumonia and bloodstream infections. Therapy should be guided by antimicrobial susceptibility testing because resistance is common [37].

4.Carbapenem-Resistant Enterobacterales (CRE)

CRE infections are associated with high mortality in critically ill patients. Treatment often requires newer β-lactam/β-lactamase inhibitor combinations or other targeted agents based on susceptibility testing.

5. Extended-Spectrum β-Lactamase (ESBL)-Producing Enterobacterales

ESBL-producing Escherichia coli and Klebsiella pneumoniae are important causes of urinary tract infections, intra-abdominal infections, and sepsis. Carbapenems are generally preferred for severe invasive infections.

6. Candida Species

Critically ill patients with prolonged ICU stay, broad-spectrum antibiotic exposure, central venous catheters, or immunosuppression are at increased risk of invasive candidiasis. Early therapy should be considered in high-risk patients after appropriate clinical evaluation [38].

CONCLUSION

Rational antibiotic use is essential for delivering high-quality care to critically ill patients in the ICU. Appropriate antibiotic selection, timely initiation of therapy, dose optimization, and culture-guided de-escalation improve treatment outcomes while limiting antimicrobial resistance and adverse effects. The integration of antimicrobial stewardship programs, rapid diagnostic techniques, and continuous monitoring further enhances patient safety and preserves the effectiveness of existing antibiotics. Continued efforts to promote evidence-based prescribing and strengthen stewardship practices are vital for improving clinical outcomes and addressing the global challenge of antimicrobial resistance.

FUNDING

Ni

INFORM CONSENT AND ETHICAL STATEMENT

Not Applicable

ACKNOWLEDGEMENT

Not Declared

AUTHOR CONTRIBUTION

All authors are contributed equally.

REFERENCES

1. Deutschman CS, Neligan PJ. Evidence-based practice of critical care. Elsevier Health Sciences; 2010.
2. Utterson K. The legal ecology of resistance: the role of antibiotic resistance in pharmaceutical innovation. eYLS (Yale Law School). 2009;31:182-186. doi:10.1097/00007611-196302000-00015.
3. Ognetti R, Vanni M, Meucci V, Parti S, Intorre L. A retrospective evaluation of Vipera aspis envenomation in dogs treated with an equine-derived F(ab')2 viperid antivenom. CINECA IRIS Institutional Research Information System, University of Pisa. 2018. Available from: http://hdl.handle.net/11568/947621
4. Waldron C, Pallmann P, Schoenbuchner S, Harris D, Brookes-Howell L, Mateus C, et al. Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT. Health Technol Assess. 2025;29(16):1-125. doi:10.3310/mbva3675.
5. Brigadoi G, Liberati C, Gres E, Barbieri E, Boreggio E, Rossin S, et al. Impact of an antibiotic stewardship program on adherence to antibiotic prescription in children admitted with urinary tract infection. Ther Adv Infect Dis. 2024;11:20499361241282824. doi:10.1177/20499361241282824.
6. Tran H. Developing predictive PK/PD models to optimise dosing regimens for antibiotics for gram-negative infections. Liverpool John Moores University; 2026. doi:10.24377/ljmu.t.00027616.
7. Kumar AA, Valakkada J, Ayyappan A, Kannath S. Basic statistics for radiologists: part 1—basic data interpretation and inferential statistics. Indian J Radiol Imaging. 2025;35(Suppl 1):S58-S73. doi:10.1055/s-0044-1796644.
8. Obolonskyi O, Kapustina O, Obolonska O. Scales for assessing pain in newborns: an integrative review for nursing practice and rehabilitation specialists. Neonatol Surg Perinat Med. 2025;15(3):197-202. doi:10.24061/2413-4260.xv.3.57.2025.27.
9. Bianchi M, Rubeo A, Costa M, Ferretti A, Di Nardo G, Parisi P, et al. Pediatric antimicrobial stewardship: current evidence and emerging challenges. Pandemics. 2026;1(1):4. doi:10.3390/pandemics1010004.
10. Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr. 2019;38(1):10-47. doi:10.1016/j.clnu.2018.05.024.
11. Abdallah EM, Alhudhaibi AM, Dahab M, Noman AA, Sharma PD, Taha TH, et al. The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development. Front Pharmacol. 2026;17:1699987. doi:10.3389/fphar.2026.1699987.
12. International Scientific and Theoretical Conference. Sectoral research XXI: characteristics and features. Primedia eLaunch LLC eBooks; 2023. doi:10.36074/scientia-03.02.2023.

13. Institute of Medicine, Board on Global Health, Forum on Microbial Threats. Antibiotic resistance: implications for global health and novel intervention strategies: workshop summary. Washington (DC): National Academies Press; 2010.
14. Wermuth CG. The practice of medicinal chemistry. Academic Press; 2011.
15. Paw HGW, Park GR. Handbook of drugs in intensive care: an A-Z guide. Cambridge: Cambridge University Press; 2000.
16. Depetris N, De Jong AEE, Meirte J, Leclerc T, Mendez JRM, Schiestl C, et al. 21st Congress of the European Burns Association (EBA). Eur Burn J. 2025;6(3):49. doi:10.3390/ebj6030049.
17. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440.
18. Arulkumaran S. Investigation of incident 50278 from time of patient's self referral to hospital on the 21st of October 2012 to the patient's death on the 28th of October 2012. Lenus, Irish Health Repository, Dr Steevens Hospital Library; 2013. Available from: http://hdl.handle.net/10147/293964
19. Cornely OA, Gow N, Hoenigl M, Warris A. 10th Trends in Medical Mycology held on 8 to 11 October 2021, Aberdeen, Scotland, organized by the European Confederation of Medical Mycology (ECMM). J Fungi. 2021;7(11):916. doi:10.3390/jof7110916.
20. Bastidas G. Zoonosis of public health interest. In: IntechOpen eBooks. 2022. doi:10.5772/intechopen.100934.
21. Miller MB, Prinzi AM, Rodino KG, Gilligan PH. Cases in medical microbiology and infectious diseases. John Wiley & Sons; 2025.
22. Waldron C, Pallmann P, Schoenbuchner S, Harris D, Brookes-Howell L, Mateus C, et al. Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT. Health Technol Assess. 2025;29(16):1-125. doi:10.3310/mbva3675.
23. Haenen A, Roukens M, Biesheuvel M, Baltink J, S DG. International Conference on Prevention and Infection Control 2023. Antimicrob Resist Infect Control. 2023;12(Suppl 1). doi:10.1186/s13756-023-01276-2.
24. Lightner AL, Sengupta V, Qian S, Ransom JT, Suzuki S, Park DJ, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19. Chest. 2023;164(6):1444-1453. doi:10.1016/j.chest.2023.06.024.
25. Tarrant C, Krockow EM, Rousham EK, Rönnerstrand B. Optimising antibiotic use: social and contextual issues. Frontiers Media SA; 2021.
26. Popular Mechanics. 2000.
27. Working Mother. 2001.
28. Doron S, Campion M. Antimicrobial stewardship in non-traditional settings: a practical guide. Springer Nature; 2023.
29. Schlossberg D, Samuel R. Antibiotic manual: a guide to commonly used antimicrobials. PMPH-USA; 2011.
30. Holmes H. Polypharmacy, an issue of clinics in geriatric medicine. Clinics: Internal Medicine. 2012.
31. Reidenberg MM. Renal function and drug action. Philadelphia: Saunders Limited; 1971.
32. Lu Y, Chen J, Fan N, Song W, Sheng H, Yang Y, et al. Machine learning models for drug-drug interaction prediction from computational discovery to clinical application. NPJ Digit Med. 2026;9(1). doi:10.1038/s41746-026-02400-3.
33. Index Medicus. 2001.
34. Aker C. Pneumothorax and pneumomediastinum in children. Turk J Thorac Cardiovasc Surg. 2024;32(Suppl 1):37-42. doi:10.5606/tgkdc.dergisi.2024.25755.
35. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55. doi:10.1093/cid/ciq146.
36. Index Medicus. 2001.
37. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023. doi:10.1093/cid/ciad428.
38. Klebsiella infections: new insights for the healthcare professional: 2011 edition: scholarly paper. ScholarlyEditions; 2012.